JZP3507 (ONC206) Phase 2 Trial for Recurrent Grade 2 or 3 Meningioma
Summary
NIH registered a Phase 2 clinical trial (NCT07533942) evaluating JZP3507 (ONC206) in patients with recurrent Grade 2 or 3 meningioma who have failed prior therapy. The single-arm study will administer oral JZP3507 and evaluate antitumor activity and safety. The trial is listed on ClinicalTrials.gov with an anticipated start date of April 16, 2026.
What changed
NIH registered a new Phase 2 clinical trial (NCT07533942) for JZP3507 (ONC206) in recurrent Grade 2 or 3 meningioma. The single-arm study will recruit participants who have failed prior therapy and receive oral doses of the drug, with evaluation of antitumor activity and safety endpoints. The trial is listed as Phase 2 with an anticipated start date of April 16, 2026.
Healthcare providers and clinical research organizations involved in neuro-oncology should monitor this trial for potential enrollment opportunities. Pharmaceutical companies conducting brain tumor research may find this registration relevant for competitive intelligence or collaborative research considerations. The trial represents standard clinical development activity for an investigational agent in a rare CNS tumor indication.
What to do next
- Monitor ClinicalTrials.gov for updates on trial status
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
Phase 2 NCT07533942 Kind: PHASE2 Apr 16, 2026
Abstract
This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.
Conditions: Meningioma
Interventions: JZP3507
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.